REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-16. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
== History == The first mention of armed groups of Chechen militants in Syria appeared in a number of media outlets at the end of 2011. In October 2012, some publications wrote that Chechens as part of the Syrian opposition forces of the FSA and Jabhat al-Nusra took part in an attack on the military base of the Syrian army air defense brigade near Aleppo. Chechen jihadists began arriving in Syria en masse mainly in 2011-2015 from Chechnya, as well as from Europe, where they left during the second Chechen War, fleeing from the war, as well as from the Pankisi Gorge of Georgia, where ethnic Chechens-Kistins, who emigrated there during the Caucasian War. Chechens occupied the second largest number among the foreign contingent of jihadists in Syria, estimates of their number range from 1,700 to 3,000 people, they played a significant role in the civil war in Syria, and several dozen well-known commanders of Syrian rebels and jihadists were Chechens by origin. Some of them were veterans of the first and second Chechen wars and used their combat experience to train the Syrian opposition and militants. They formed their own armed detachments and jamaats, which were also joined by other militants from the North Caucasus, as well as Syrians and jihadists from all over the Middle East. According to representatives of the Chechen diaspora in Europe, hundreds of Chechens from Europe went to Syria to fight in the ranks of the Syrian opposition against the government army of Bashar al-Assad.
The four substrates of this enzyme are 1-deoxy-11-oxopentalenic acid, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. It products are neopentalenolactone D, oxidised NADP+, and water. The starting ketone is made as part of a biosynthetic pathway in Streptomyces avermitilis which leads to pentalenolactone and related compounds. The enzyme is a Baeyer-Villiger monooxygenase that uses flavin adenine dinucleotide as a cofactor.
=== Classification === Epulis (literally, 'on the gingiva') is a general term for any gingival or alveolar tumor (i.e. lump on the gum). This term describes only the location of a lump and has no implication on the histologic appearance of a lesion. Epulis is also sometimes used synonymously with epulis fissuratum, however other conditions are classified as epulides, e.g. giant cell epulis (peripheral giant cell granuloma), ossifying fibroid epulis (peripheral ossifying fibroma), and congenital epulis.
This was the first time a two-dimensional semiconducting MOF was demonstrated to be used in opto-electronic devices. Cu3(HHTP)2 is a 2D MOF structure, and there are limited examples of materials which are intrinsically conductive, porous, and crystalline. Layered 2D MOFs have porous crystalline structure showing electrical conductivity. These materials are constructed from trigonal linker molecules (phenylene or triphenylene) and six functional groups of –OH, -NH2, or –SH. The trigonal linker molecules and square-planarly coordinated metal ions such as Cu2+, Ni2+, Co2+, and Pt2+ form layers with hexagonal structures which look like graphene in larger scale. Stacking of these layers can build one-dimensional pore systems. Graphene-like 2D MOFs have shown decent conductivities. This makes them a good choice to be tested as electrode material for evolution of hydrogen from water, oxygen reduction reactions, supercapacitors, and sensing of volatile organic compounds (VOCs). Among these MOFs, Cu3(HHTP)2 has exhibited the lowest conductivity, but also the strongest reaction in sensing of VOCs.
Sources: en.wikipedia.org
=== Opposition: 1975–79 === Heseltine did not work easily with women as senior colleagues, as was shown by the difficulty experienced by Elinor Goodman in obtaining promotion from secretary to journalist at Campaign, and his reluctance to let Josephine Hart sit on the Haymarket Board. Heseltine fully expected to be sacked from the Shadow Cabinet by the new leader (as Peter Walker was at this time), but was retained, in part because Thatcher was impressed by his fierce opposition to Benn's Industry Bill, and partly because a senior figure, possibly Geoffrey Howe, argued for his retention. Heseltine first emerged as a platform orator at the Conservative National Council in March 1975, and then at the autumn conferences in 1975 and 1976 (where he likened Labour to a one-legged army marching "Left, left, left"). He dictated his speech ideas beforehand to his scriptwriters, who had to discard a good deal of unintelligible material. His reputation was derived not from any factual content or argument, but from the force and brio of his delivery – it was said of him that he could "find the party's clitoris". There was talk of his being appointed Party Chairman (in charge of the party organisation and of campaigning across the country) in place of Peter Thorneycroft. In the summer of 1975, Heseltine persuaded the Shadow Cabinet not to oppose the Labour Government's bailout of British Leyland because of the risk to marginal seats (including some Cowley workers in northern wards of his own Henley seat).
== T == Celia White Tabor (1918–2012). American biochemist at the NIH, expert on the biosynthesis of polyamines. Herbert Tabor (1918–2020). American biochemist at NIH who studied the function of polyamines and their role in human health and disease. He was editor-in-chief of the Journal of Biological Chemistry for nearly 40 years. Member Natl. Acad. Sci. USA. Charles Tanford (1921–2009). American protein chemist at Duke University, known for analysis of the hydrophobic effect. Member Natl. Acad. Sci. USA. Ignacio Tinoco Jr. (1930–2016). American chemist at UC Berkeley, known for his pioneering work on RNA folding. Member Natl. Acad. Sci. USA. Arne Tiselius FRS (foreign associate) (1902–1971). Swedish biochemist at the University of Uppsala, who developed protein electrophoresis. Nobel Prize for Chemistry (1948). Foreign associate Natl. Acad. Sci. USA. Victor Trikojus CBE (1902–1985). Australian biochemist, head of the School of Biochemistry at the University of Melbourne (1943–1968). Joint discoverer of triiodothyronine (T3) with Frank Hird in 1948. Chen-Lu Tsou (邹承鲁 Zou Chenglu in Pinyin, 1923–2006). Chinese biochemist at the Academia Sinica, known for work on enzyme inactivation kinetics, and even more as the "face of Chinese biochemistry" for many years in the west. Member of the Academia Sinica.
=== Signs and symptoms === Death caps have been reported to taste pleasant. This, coupled with the delay in the appearance of symptoms—during which time internal organs are being severely, sometimes irreparably, damaged—makes them particularly dangerous. Initially, symptoms are gastrointestinal in nature and include colicky abdominal pain, with watery diarrhea, nausea, and vomiting, which may lead to dehydration if left untreated, and, in severe cases, hypotension, tachycardia, hypoglycemia, and acid–base disturbances. These first symptoms resolve two to three days after the ingestion. A more serious deterioration signifying liver involvement may then occur—jaundice, diarrhea, delirium, seizures, and coma due to fulminant liver failure and attendant hepatic encephalopathy caused by the accumulation of normally liver-removed substances in the blood. Kidney failure (either secondary to severe hepatitis or caused by direct toxic kidney damage) and coagulopathy may appear during this stage. Life-threatening complications include increased intracranial pressure, intracranial bleeding, pancreatic inflammation, acute kidney failure, and cardiac arrest. Death generally occurs six to sixteen days after the poisoning. It is noticed that after up to 24 hours have passed, the symptoms seem to disappear and the person might feel fine for up to 72 hours. Symptoms of liver and kidney damage start 3 to 6 days after the mushrooms were eaten, with the considerable increase of the transaminases. Mushroom poisoning is more common in Europe than in North America.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.